Post by Leigh Ann A.

In May, #FDA approvals include Xocova, the first oral option to help prevent COVID-19 following exposure. In #cancer, Decnupaz gained approval for blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer, Beqalzi received accelerated approval for relapsed or refractory mantle cell lymphoma, and Veppanu became the first PROTAC therapy approved, targeting estrogen receptor-positive, HER2-negative advanced #breastcancer. Baxfendy became the first aldosterone synthase inhibitor for hypertension, and Hepcludex received accelerated approval for chronic hepatitis delta. Trimbow introduced a new triple combination inhaler for #asthma maintenance, Zaynich added a combination antibiotic for complicated urinary tract infections (#UTI), and Differin Epiduo #Acne Gel moved to nonprescription use. The first #biosimilars for Simponi and Simponi Aria (Immgolis and Immgolis Intri) were also approved as well as Ennumo, the eighth biosimilar for Neulasta. https://lnkd.in/eYY-JMJ2 #Xocova #Decnupaz #Beqalzi #Veppanu #Baxfendy #Hepcludex #Trimbow #Zaynich #DifferinEpiduo #Immgolis #Ennumo